Another perspective on Pfizer's R&D move...
http://www.forbes.com/sites/matthewh...dical-surgery/
Whether or not it's the right move remains to be seen, but there's clearly a lot more to it than "hey, let's chop R&D and buy back shares so we can boost EPS and get a big bonus".
Bookmarks